A medicine demonstrates strong clinical efficacy and acceptable safety in trials, but the manufacturing process shows variability between batches. What is the MOST appropriate regulatory concern?

Question

BlackTom AI · Accepted Answer

Consistent product quality under Good Manufacturing Practice (GMP) is a precondition for reliable safety and efficacy in the real world.

1. Relevant knowledge points and concepts
- Regulatory authorities require both clinical evidence and validated, controlled manufacturing processes (CMC: chemistry, manufacturing and controls). 
- Batch-to-batch variability can change active ingredient content, impurities, potency, release characteristics or sterility, which directly affect safety and effectiveness. 
- Approval decisions consider risk that clinical-trial performance will not be reproducible when product quality is inconsistent.

2. Step-by-step reasoning
- Clinical trials demonstrate efficacy and acceptable safety for the batches used in those studies. 
- If manufacturing shows variability, subsequent commercial batches may differ from trial material. 
- Differences can reduce efficacy (subpotent batches) or introduce safety risks (overdose, impurities, contamination). 
- Regulators therefore prioritize controlling variability before or as a condition of approval.

3. Calculations / intermediate steps
- No numerical calculations are required. The logical chain is: demonstrated efficacy for trial batches + observed manufacturing variability → potential for non-equivalent commercial batches → potential compromise of safety/efficacy.

4. Why the correct answer is correct
- Option c states that lack of consistent quality may compromise safety and efficacy in real-world use, which precisely captures the regulatory concern about uncontrolled manufacturing variability undermining clinical benefits or introducing risks.

5. Why the other options are incorrect
- a. Incorrect: Demonstrated efficacy does not make variability acceptable; regulators require consistent product quality. 
- b. Incorrect: Variability affects product quality and patient safety/efficacy, not merely cost, and is central to regulatory approval. 
- d. Incorrect: Strong clinical data alone do not override the need for validated, reproducible manufacturing controls.

6. Conclusion
- The most appropriate regulatory concern is c. Lack of consistent quality may compromise safety and efficacy in real-world use. This matches the provided correct answer.

A medicine demonstrates strong clinical efficacy and acceptable safety in trials, but the manufacturing process shows variability between batches. What is the MOST appropriate regulatory concern?单项选择题

类似问题

In the TGA prescription medicines registration process, what is the purpose of the Section 31 (s31) request?

You own a bond that pays $64 in interest annually. The face value is $1,000 and the current market price is $1,021.61. The bond matures in 11 years. What is the yield to maturity?

Which of the following statements is CORRECT?

It will cost $9,600 to acquire an ice cream cart that is expected to produce cash inflows of $3,600 a year for three years. After the three years, the cart is expected to be worthless. What is the payback period?

更多留学生实用工具

智能学习助手

风格化写作助手

论文查重助手

文献引用助手

课堂转译助手

课堂笔记助手

Quiz搜索助手

学校历年真题

智能刷题助手

智能匹配练习

希望你的学习变得更简单